| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8221471 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 8 Pages |
Abstract
Our preliminary data suggest that rhDNase did not significantly improve study primary endpoints of QOL measures compared with the placebo group. However, there was a significant improvement in secondary endpoints of clinically assessed OPS and DNA concentration compared with placebo in H&N cancer patients treated with CRT. Further investigation in larger numbers of patients is warranted.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Bharat B. MD, Edward PhD, Samir MD, Mark MD, Amit BS, Kirk PhD,